Randomized Study to Evaluate the Use of High-Dose Therapy as Part of Primary Treatment for “Aggressive” Lymphoma
Ulrich Kaiser, Irmgard Uebelacker, Ulrich R. Abel et al. · Journal of Clinical Oncology · 2002
PURPOSE: This trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group compares the use of high-dose therapy (HDT) as part of primary treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus etoposide followed by involved-field (IF) radiotherapy in a randomized, multicenter, phase III study. PATIENTS AND METHODS: Three hundred twelve patients with "aggressive" non-Hodgkin's lymphoma aged <or= 60 years with elevated serum lactate dehydrogenase levels were included from 1990 to 1997. Patients with at least a minor response after two cycles of CHOEP (CHOP + etoposide 3 x 100 mg/m(2)) were to receive three further cycles of CHOEP followed by IF radiotherapy (arm A) or one further cycle of CHOEP followed by autologous stem-cell transplantation and IF radiotherapy (arm B). RESULTS: Among 158 patients randomized to arm B, 103 (65%) received HDT. The complete remission rate at the end of treatment was 62.9% in arm A and 69.9% in arm B. With a median observation time of 45.5 months, overall survival for all 312 patients was 63% after 3 years (63% for arm A, 62% for arm B; P =.68). Event-free survival was 49% for arm A versus 59% for arm B (P =.22). Relapse in arm B was associated with a significantly worse survival rate than relapse in arm A (P <.05). Relapse after HDT occurred early (median interval, 3 months). Six patients developed secondary neoplasia, three in arm A and three in arm B. CONCLUSION: Results of the randomized trial comparing CHOP-like chemotherapy with early HDT do not support the use of HDT with carmustine, etoposide, cytarabine, and melphalan following shortened standard chemotherapy.
Cited by 139 works. doi:10.1200/jco.2002.07.075
Authors
- Ulrich Kaiser
- Irmgard Uebelacker
- Ulrich R. Abel
- Josef Birkmann
- Lorenz H. P. Trümper
- Harald Schmalenberg
- Tunca Karakas
- Bernd Metzner
- DIETER KURT HOSSFELD
- Helge G. Bischoff
- Marcel Reiser
- Peter E. Müller
- Luisa Mantovani
- Marc Grundeis
- Frank Rothmann
- Cay-Uwe von Seydewitz
- Rolf Michael Mesters
- Ernst U. Steinhauer
- Dorothea Krahl
References
- A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]
- A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
- UPDATED KIEL CLASSIFICATION FOR LYMPHOMAS
- A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma study group
- Treatment of Non-Hodgkin's Lymphoma
- Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin’s Lymphoma: Final Analysis of the Prospective LNH87–2 Protocol—A Groupe d’Etude des Lymphomes de l’Adulte Study
- High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma
- Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.